Medivation, Astellas look to widen use of Xtandi cancer drug

|About: Medivation, Inc. (MDVN)|By:, SA News Editor

Medivation (MDVN +2% premarket) and Astellas Pharma (ALPMF) have filed a request with the FDA to widen the use of their Xtandi product to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.

Xtandi is already approved for the treatment of patients with mCRPC who have received Docetaxel chemotherapy.

The companies intend to file a similar request in the EU later this year. (PR)